{
  "analysis_timestamp": "2026-01-09T03:11:12.577033",
  "analyses": {
    "benefit_factor": {
      "benefit_sub_factor": "Off label",
      "weight": 10,
      "score": 1,
      "weighted_score": 10,
      "cdsco_approved": false,
      "usfda_approved": false
    },
    "market_experience": {
      "experience_sub_factor": "Established indication (>5Y, approved widely)",
      "weight": 90,
      "score": 5,
      "weighted_score": 450,
      "years_in_market": 29
    },
    "pubmed_evidence": {
      "evidence_sub_factor": "Low evidence (limited data, uncertain)",
      "weight": 30,
      "score": 1,
      "weighted_score": 30,
      "rct_count": 1
    },
    "raw_data": {
      "drug": "Atorvastatin",
      "diagnosis": "Chronic Liver Disease",
      "patient_info": {
        "age": 60,
        "gender": "Male",
        "diagnosis": "Hyperlipidemia, Chronic Liver Disease",
        "condition": "decompensated cirrhosis",
        "allergies": [],
        "date_of_assessment": "2026-01-06"
      },
      "regulatory": {
        "drug": "Atorvastatin",
        "condition": "Chronic Liver Disease",
        "cdsco_approved": false,
        "usfda_approved": false,
        "output": "Atorvastatin is not approved for use in Chronic Liver Disease as per the CDSCO (Indian health regulatory body) and also as per USFDA's USPI (United States Prescriber information). Please review the iBR score and consider alternative medications that are approved by regulatory bodies for treating Chronic Liver Disease."
      },
      "market_experience": {
        "found": true,
        "generic_name": "ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM",
        "approval_date": "17-Dec-1996",
        "years": 29,
        "output": "ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM is first approved by USFDA on 17-Dec-1996 and first approved by CDSCO on [CDSCO approval date not available]. ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM is in the market for more than 29 years of post-market experience."
      },
      "pubmed_evidence": {
        "rct_count": 1,
        "top_conclusions": [
          {
            "title": "Atorvastatin for prevention of disease progression and hospitalisation in liver cirrhosis: protocol for a randomised, double-blind, placebo-controlled trial.",
            "conclusion": "The trial is registered in clinicaltrials.gov (NCT04072601) and in clinicaltrialsregister.eu (EudraCT 2019-001806-40) (Pre-results)."
          }
        ]
      }
    }
  }
}